Literature DB >> 21167863

Vaccine generated immunity targets an HPV16 E7 HLA-A2.1-restricted CD8(+) T cell epitope relocated to an early gene or a late gene of the cottontail rabbit papillomavirus (CRPV) genome in HLA-A2.1 transgenic rabbits.

Callie E Bounds1, Jiafen Hu, Nancy M Cladel, Karla Balogh, Neil D Christensen.   

Abstract

The newly established HLA-A2.1 transgenic rabbit model has proven useful for testing the immunogenicity of well known and computer-predicted A2-restricted epitopes. In the current study we compared the protective immunity induced to a preferred HPV16 E7 A2-restricted epitope that has been relocated to positions within the CRPV E7 gene and the CRPV L2 gene. Epitope expression from both the E7 protein and the L2 protein resulted in increased protection against viral DNA challenge of the HLA-A2.1 transgenic rabbits as compared to control-vaccinated rabbit groups. These data indicate that proteins expressed at both early and late time points during a natural papillomavirus infection can be targeted by epitope-specific immunity and indicate this immunity is increased to early rather than late expressed proteins of papillomaviruses. This study also highlights the broad utility of the HLAA2.1 transgenic rabbit model for testing numerous immunological factors involved in vaccine generated protective immunity. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167863      PMCID: PMC3065889          DOI: 10.1016/j.vaccine.2010.12.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  37 in total

1.  Use of a rapid, efficient inoculation method to induce papillomas by cottontail rabbit papillomavirus DNA shows that the E7 gene is required.

Authors:  J L Brandsma; Z H Yang; S W Barthold; E A Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection.

Authors:  R Han; C A Reed; N M Cladel; N D Christensen
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

3.  Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes.

Authors:  P K Nicholls; P F Moore; D M Anderson; R A Moore; N R Parry; G W Gough; M A Stanley
Journal:  Virology       Date:  2001-04-25       Impact factor: 3.616

4.  Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine.

Authors:  M P Velders; S Weijzen; G L Eiben; A G Elmishad; P M Kloetzel; T Higgins; R B Ciccarelli; M Evans; S Man; L Smith; W M Kast
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

5.  In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas.

Authors:  N D Christensen; M D Pickel; L R Budgeon; J W Kreider
Journal:  Antiviral Res       Date:  2000-11       Impact factor: 5.970

Review 6.  The immunology of animal papillomaviruses.

Authors:  P K Nicholls; M A Stanley
Journal:  Vet Immunol Immunopathol       Date:  2000-02-25       Impact factor: 2.046

7.  Genetic analysis of CRPV pathogenesis: the L1 open reading frame is dispensable for cellular transformation but is required for papilloma formation.

Authors:  M Nasseri; C Meyers; F O Wettstein
Journal:  Virology       Date:  1989-05       Impact factor: 3.616

Review 8.  Animal models of papillomavirus pathogenesis.

Authors:  M Saveria Campo
Journal:  Virus Res       Date:  2002-11       Impact factor: 3.303

9.  Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits.

Authors:  Jiafen Hu; Ricai Han; Nancy M Cladel; Martin D Pickel; Neil D Christensen
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge.

Authors:  Pirouz Daftarian; Saima Ali; Rahul Sharan; Simon F Lacey; Corinna La Rosa; Jeff Longmate; Christopher Buck; Robert F Siliciano; Don J Diamond
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

View more
  6 in total

1.  Orf Virus-Based Therapeutic Vaccine for Treatment of Papillomavirus-Induced Tumors.

Authors:  M Schneider; M Müller; A Yigitliler; J Xi; C Simon; T Feger; H-J Rziha; F Stubenrauch; H-G Rammensee; T Iftner; R Amann
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

Review 2.  The rabbit papillomavirus model: a valuable tool to study viral-host interactions.

Authors:  Nancy M Cladel; Xuwen Peng; Neil Christensen; Jiafen Hu
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

3.  Prediction and identification of human leukocyte antigen-A2-restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein.

Authors:  He Wang; Lilai Chen; Weihong Ma; Yue Zeng; Lu Qin; Mengjie Chen; Li Li
Journal:  Oncol Lett       Date:  2018-06-01       Impact factor: 2.967

Review 4.  Rabbit Models for Studying Human Infectious Diseases.

Authors:  Xuwen Peng; John A Knouse; Krista M Hernon
Journal:  Comp Med       Date:  2015-12       Impact factor: 0.982

Review 5.  Gene Editing in Rabbits: Unique Opportunities for Translational Biomedical Research.

Authors:  Jie Xu; Jifeng Zhang; Dongshan Yang; Jun Song; Brooke Pallas; Chen Zhang; Jiafen Hu; Xuwen Peng; Neil D Christensen; Renzhi Han; Y Eugene Chen
Journal:  Front Genet       Date:  2021-01-28       Impact factor: 4.599

Review 6.  Modeling HPV-Associated Disease and Cancer Using the Cottontail Rabbit Papillomavirus.

Authors:  Nancy M Cladel; Jie Xu; Xuwen Peng; Pengfei Jiang; Neil D Christensen; Zhi-Ming Zheng; Jiafen Hu
Journal:  Viruses       Date:  2022-09-04       Impact factor: 5.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.